Peptron, Inc.

Equities

A087010

KR7087010005

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 16/05/2024 BST			5-day change	1st Jan Change
31,300 ^KRW	+1.95%		-3.10%	-22.24%

2023	Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	MT
2023	Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	CI

Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.

October 04, 2023 at 08:21 am

From October 1, 2023 to October 4, 2023, the company has repurchased 0 shares, representing 0% for KRW 0 million. With this, the company has completed the repurchase of 73,961 shares, representing 0.36% for KRW 891.08 million under the buyback announced on April 5, 2023.

Latest news about Peptron, Inc.

Invex Therapeutics, Peptron End Collaboration, Manufacturing Deal	12-22	MT
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	04/10/23	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	04/10/23	CI
Peptron, Inc.'s Equity Buyback announced on April 5, 2023, has expired with 73,961 shares, representing 0.36% for KRW 891.08 million.	03/10/23	CI
Tranche Update on Peptron, Inc.'s Equity Buyback Plan announced on April 5, 2023.	07/07/23	CI
Peptron, Inc. announces an Equity Buyback for KRW 3,000 million worth of its shares.	05/04/23	CI
Peptron, Inc. authorizes a Buyback Plan.	04/04/23	CI
Peptron, Inc. Establishes Bioequivalence of PT105	28/11/22	CI
Invex Therapeutics Ltd Announces the Signing of a Long Term Collaboration and Manufacturing Agreement with Peptron, Inc	27/09/21	CI
Qilu Pharmaceutical and Peptron Sign License Agreement for Anti-MUC1 ADC	16/04/21	CI
Peptron, Inc. Announces Published Data Showing a New Sustained-Release Exendin-4 Formulation Prevents Neurodegeneration in a Parkinson's Disease Model	16/07/18	CI
Peptron, Inc. announced that it has received $24 million in funding	22/04/18	CI
Peptron, Inc. announced that it has received KRW 25.5 billion in funding from Industrial Bank of Korea	30/01/18	CI
Peptron, Inc. announced that it expects to receive KRW 25.5 billion in funding from Industrial Bank of Korea	28/01/18	CI
Peptron, Inc. announced that it has received funding from E&Investment,Inc.	24/04/16	CI
Peptron, Inc. announced that it has received KRW 2 billion in funding from UNO & COMPANY Ltd.	24/04/16	CI
Peptron, Inc. announced that it expects to receive KRW 2 billion in funding from UNO & COMPANY Ltd.	19/04/16	CI
Peptron, Inc.(KOSDAQ:A087010) added to Russell Global Index	01/10/15	CI
Peptron, Inc.(KOSDAQ:A087010) added to S&P Global BMI Index	21/09/15	CI
Peptron, Inc. has completed an IPO in the amount of KRW 13.04 billion.	17/07/15	CI
Peptron, Inc. has filed an IPO.	04/09/14	CI
UNO&COMPANY Ltd. acquired 3.66% stake in Peptron, Inc. for approximately KRW 1 billion.	10/02/14	CI

Chart Peptron, Inc.

Duration

Period

More charts

Company Profile

Peptron, Inc. is a Korea-based company principally engaged in the development, manufacture and distribution of sustained-release medications. The Company mainly produces peptides as drug materials mainly for prostate cancer, hyperpituitarism, diabetes and neurodegenerative disorders. The Company also provides peptide synthesis services. The Company manufactures raw material medicines and some functional cosmetics. The Company distributes its products within domestic market and to overseas markets.

Sector

Biotechnology & Medical Research

Calendar

13/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
PEPTRON, INC.	-22.24%	477M
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	115B
REGENERON PHARMACEUTICALS, INC.	+11.84%	106B
ARGENX SE	-1.05%	21.96B
BIONTECH SE	-14.15%	21.84B
GENMAB A/S	-5.29%	19.21B
BEIGENE, LTD.	-4.16%	18.08B
WUXI APPTEC CO., LTD.	-38.29%	17.71B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.32B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.42B

Bio Therapeutic Drugs